Medications for Mucopolysaccharidosis Type 2 (MPS II, Hunter Syndrome)
These are drugs that have been approved by the US Food and Drug Administration (FDA), meaning they have been determined to be safe and effective for use in Mucopolysaccharidosis Type 2 (MPS II, Hunter Syndrome).
Found 1 Approved Drug for Mucopolysaccharidosis Type 2 (MPS II, Hunter Syndrome)
Elaprase
Generic Name
Idursulfase
Elaprase
Generic Name
Idursulfase
Form: Solution
Method of administration: Intravenous
FDA approval date: July 24, 2006
Classification: Hydrolytic Lysosomal Glycosaminoglycan-specific Enzyme
ELAPRASE is indicated for patients with Hunter syndrome (Mucopolysaccharidosis II, MPS II). ELAPRASE has been shown to improve walking capacity in patients 5 years and older. In patients 16 months to 5 years of age, no data are available to demonstrate improvement in disease-related symptoms or long term clinical outcome; however, treatment with ELAPRASE has reduced spleen volume similarly to that of adults and children 5 years of age and older. The safety and efficacy of ELAPRASE have not been established in pediatric patients less than 16 months of age [see Use in Specific Populations.
Showing 1-1 of 1
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances